This content is machine translated Biologics for atopic dermatitis Th2 cytokines in focus: proven and new targets The range of antibody therapies for atopic dermatitis (AD) has expanded once again in Europe. In addition to dupilumab and tralokinumab, lebrikizumab is another biologic available in this country that...…
View Post 2 min This content is machine translated Atopic dermatitis in childhood and adolescence Dupilumab proves itself in daily practice In the “BioDay Registry” study, treatment with dupilumab in pediatric patients with atopic dermatitis in a “real world” setting resulted in significant improvement in disease severity and associated symptoms. Tolerability…
View Post 6 min This content is machine translated Atopic eczema EuroGuiDerm guideline – overview of current recommendations for system therapy Recently, there have been significant advances in the treatment of atopic dermatitis, including several new systemic therapeutic options overcoming regulatory hurdles. This has also been incorporated into the EuroGuiDerm guideline…
View Post 4 min This content is machine translated Dupilumab in atopic dermatitis New post-hoc analysis: consistent symptom improvement over 52 weeks. In atopic dermatitis, long-term symptom control is one of the overriding therapeutic goals. A recently published post-hoc analysis demonstrated that patients treated with dupilumab achieved sustained and consistent improvement in…
View Post 4 min This content is machine translated Atopic dermatitis: biologics Dupilumab also effective and safe in under 12-year-olds In Switzerland, the approval of the highly effective biologic Dupilumab in the indication area of atopic dermatitis has so far been limited to adult and adolescent patients aged 12 years…
View Post 3 min This content is machine translated Case series Chronic prurigo in atopic patients: successful treatment with dupilumab. A case series of patients with prurigo was published in the journal Acta Dermato Venerologica. After multiple unsuccessful previous therapies, the use of dupilumab resulted in a significant improvement in…
View Post 4 min This content is machine translated Atopic dermatitis Empirical data with dupilumab confirm the empirical evidence The biologic Dupilumab has proven itself under “real-life” conditions and has already received an extension of approval in the EU for the age group 12 years and older. At the…
